Denali Therapeutics (DNLI) Total Liabilities: 2017-2025
Historic Total Liabilities for Denali Therapeutics (DNLI) over the last 8 years, with Sep 2025 value amounting to $129.4 million.
- Denali Therapeutics' Total Liabilities fell 4.50% to $129.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $129.4 million, marking a year-over-year decrease of 4.50%. This contributed to the annual value of $144.5 million for FY2024, which is 17.51% up from last year.
- Denali Therapeutics' Total Liabilities amounted to $129.4 million in Q3 2025, which was down 7.01% from $139.2 million recorded in Q2 2025.
- In the past 5 years, Denali Therapeutics' Total Liabilities registered a high of $442.6 million during Q1 2023, and its lowest value of $115.5 million during Q2 2024.
- In the last 3 years, Denali Therapeutics' Total Liabilities had a median value of $129.4 million in 2025 and averaged $158.3 million.
- Per our database at Business Quant, Denali Therapeutics' Total Liabilities spiked by 201.10% in 2021 and then plummeted by 71.62% in 2024.
- Quarterly analysis of 5 years shows Denali Therapeutics' Total Liabilities stood at $441.9 million in 2021, then declined by 5.44% to $417.8 million in 2022, then plummeted by 70.57% to $123.0 million in 2023, then grew by 17.51% to $144.5 million in 2024, then decreased by 4.50% to $129.4 million in 2025.
- Its last three reported values are $129.4 million in Q3 2025, $139.2 million for Q2 2025, and $148.7 million during Q1 2025.